Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

ORR´ï71%£¡ÔÙÉúÔªBCMA/CD3Ë«¿¹»ñFDAÓÅÏÈÉóÆÀ

2024-02-22
|
»á¼ûÁ¿£º

΢ÐÅͼƬ_20240218154108¸±±¾.jpg

Ò½ÏßÒ©ÎÅ

1. 2ÔÂ21ÈÕ£¬£¬£¬£¬ÔÙÉúÔªÐû²¼£¬£¬£¬£¬ÃÀ¹úFDAÒѽÓÊÜÆä°ÐÏòBϸ°û³ÉÊ쿹ԭ£¨BCMA£©ÓëCD3µÄË«ÌØÒìÐÔ¿¹ÌåÁÆ·¨linvoseltamabµÄÉúÎïÖÆÆ·ÔÊÐíÉêÇ루BLA£©²¢ÊÚÓèÓÅÏÈÉóÆÀ×ʸñ£¬£¬£¬£¬ÓÃÒÔÖÎÁÆ»¼Óи´·¢/ÄÑÖÎÐÔ£¨R/R£©¶à·¢ÐÔ¹ÇËèÁö£¨MM£©µÄ³ÉÄ껼Õß¡£¡£¡£¡£¡£¡£

2. 2ÔÂ21ÈÕ£¬£¬£¬£¬¹ú¼ÒÒ©¼à¾ÖÐû²¼Í¨¸æ£¬£¬£¬£¬×¿ºÍÒ©Òµ¼¯ÍÅÉ걨µÄÖÐÒ©1.1ÀàÁ¢ÒìÒ©¾Åζֹ¿È¿Ú·þÒº»ñÅúÉÏÊС£¡£¡£¡£¡£¡£¸ÃÒ©Æ·ÓÐÐû·ÎÖ¹¿È¹¦Ð§£¬£¬£¬£¬ÓÃÓÚ¼±ÐÔÆø¹Ü-Ö§Æø¹ÜÑ×ÖÐÒ½±æÖ¤Êô·çÈÈÖ¤µÄ¿ÈËÔ¡£¡£¡£¡£¡£¡£

3. 2ÔÂ19ÈÕ£¬£¬£¬£¬NMPA¹ÙÍøÏÔʾ£¬£¬£¬£¬º¼ÖݺÍÔóÀ¤ÔªÒ©ÒµµÄµØÇüÔÐͪƬ£¬£¬£¬£¬»ñÅúÉÏÊУ¬£¬£¬£¬²¢ÊÓͬͨ¹ýÒ»ÖÂÐÔÆÀ¼Û£¬£¬£¬£¬ÊǺ£ÄÚµÚ¶þ¼Ò»ñÅúµÄµØÇüÔÐͪƬ·ÂÖÆÒ©¡£¡£¡£¡£¡£¡£µØÇüÔÐͪÊÇÒ»ÖÖ¿Ú·þ»îÐÔÔм¤ËØ£¬£¬£¬£¬¿ÉÓÃÓÚÖÎÁÆÄÚÔ´ÐÔÔÐͪȱ·¦ÒýÆðµÄ¼²²¡¡£¡£¡£¡£¡£¡£

4. ¿ËÈÕ£¬£¬£¬£¬±±¾©Î¨Ô´Á¢¿µÉúÎï¿Æ¼¼¹É·ÝÓÐÏÞ¹«Ë¾1ÀàÐÂÒ©WG1025»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÒ©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡£¡£¡£¡£¡£¡£WG1025ÊÇÎÒ¹«Ë¾Ñз¢µÄ¾ßÓÐ×ÔÖ÷֪ʶ²úȨµÄÁ¢ÒìÐÍ»ùÒòÖÎÁÆÖÆÆ·£¬£¬£¬£¬ÄâÓÃÓÚÆ¤·ôÒÅ´«²¡ÓªÑø²»Á¼ÐÍ´óðåÐÔ±íÆ¤ËɽâÖ¢£¨DEB£©µÄÖÎÁÆ¡£¡£¡£¡£¡£¡£

ͶÈÚÒ©ÊÂ

1. 2ÔÂ20ÈÕ£¬£¬£¬£¬ºËÖÛÒ½Ò©Ðû²¼ÓëARTBIO¹«Ë¾¸æ¿¢¶À¼ÒÕ½ÂÔÏàÖú¡£¡£¡£¡£¡£¡£ºËÖÛÒ½Ò©ÊÇÒ»¼ÒרעÓÚÐÂÐͰÐÏò·ÅÉäÐÔÅäÌåÒ©Îï·¢Ã÷¡¢¿ª·¢ºÍ¹¤Òµ»¯µÄÉúÎï¿Æ¼¼¹«Ë¾¡£¡£¡£¡£¡£¡£ARTBIOÊÇÒ»¼ÒÁÙ´²½×¶ÎµÄ·ÅÉäÐÔÒ©Î﹫˾£¬£¬£¬£¬ÖÂÁ¦ÓÚÑз¢ÐÂÐͦÁºËËØ·ÅÉäÐÔÅäÌåÁÆ·¨¡£¡£¡£¡£¡£¡£Æ¾Ö¤Ë«·½Ç©ÊðµÄЭÒ飬£¬£¬£¬ºËÖÛÒ½Ò©½«×÷ΪARTBIOµÄ¶À¼ÒÕ½ÂÔÏàÖúͬ°é£¬£¬£¬£¬Ê¹ÓÃAlphaDirectºËËØÊèÉ¢´¿»¯¼¼ÊõÉú²úǦ212£¨???Pb£©ºËËØ¡£¡£¡£¡£¡£¡£Í¬Ê±£¬£¬£¬£¬ºËÖÛÒ½Ò©½«»ñµÃAB001ÔÚ´óÖлªÇø£¨°üÀ¨Öйú´ó½¡¢Ïã¸Û¡¢°ÄÃźĮ́ÍåµØÇø£©µÄ¿ª·¢ÓëÉÌÒµ»¯È¨Òæ¡£¡£¡£¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1. 2ÔÂ22ÈÕ£¬£¬£¬£¬Ê×¶¼Ò½¿Æ´óѧ¼Ö½¨Æ½ÍŶÓÔÚ¹ú¼Ê×ÅÃûҽѧÆÚ¿¯NEW ENGLAND JOURNAL OF MEDICINE (IF 159)ÔÚÏß½ÒÏþÌâΪ¡°Biomarker Changes during 20 Years Preceding Alzheimer¡¯s Disease¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬£¬¸ÃÑо¿¸ÃÑо¿¼ì²éÁËÀ´×ÔÖйúÈÏÖªÓëÀÏ»¯Ñо¿(COAST)µÄÒ»×éǶÌ×Ñо¿µÄ¼ÓÈëÕߣ¬£¬£¬£¬Ä¿µÄÊÇÔ¤¼Æ×îÖÕ±»Õï¶ÏΪ°¢¶û´Äº£Ä¬²¡µÄ¼ÓÈëÕߵļ¸ÖÖÄÔ¼¹ÒºÉúÎï±ê¼ÇÎïµÄת±ä¹ì¼££¬£¬£¬£¬²¢ÆÀ¹ÀÕâЩ¼ÓÈëÕßÓë䱬·¢°¢¶û´Äº£Ä¬²¡µÄ¼ÓÈëÕßµÄÉúÎï±ê¼ÇÎïת±ä¡£¡£¡£¡£¡£¡£

[1]Jianping Jia, Yuye Ning, Meilin Chen,, et al. Biomarker Changes during 20 Years Preceding Alzheimer¡¯s Disease. DOI:10.1056/NEJMoa2310168

Ïà¹ØÐÂÎÅ
ÔÙÉúÔª¡°first-in-class¡±½µÖ¬ÁÆ·¨»ñFDAÅú׼ح¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2023-03-23
3ÔÂ22ÈÕ£¬£¬£¬£¬ÔÙÉúÔª£¨Regeneron£©¹«Ë¾Ðû²¼£¬£¬£¬£¬¸Ã¹«Ë¾¿ª·¢µÄ¡°first-in-class¡±½µÖ¬ÁÆ·¨Evkeeza£¨evinacumab£©ÒÑ»ñFDAÅú×¼£¬£¬£¬£¬ÓÃÓÚºÍÆäËü½µµÍµÍÃܶÈÖ¬ÂѰ׵¨¹Ì´¼£¨LDL-C£©µÄÁÆ·¨ÁªÓ㬣¬£¬£¬ÖÎÁÆ5-11ËêÒÔÉÏ´¿ºÏ×Ó¼Ò×åÐԸߵ¨¹Ì´¼ÑªÖ¢£¨HoFH£©»¼Õß¡£¡£¡£¡£¡£¡£EvkeezaÊÇFDAÅú×¼ÓÃÒÔ¿ØÖÆÄê½ö5ËêHoFH»¼ÕßLDL-CˮƽµÄµÚÒ»¿îѪ¹ÜÌìÉúËØÑùÂѰ×3£¨ANGPTL3£©ÒÖÖÆ¼Á¡£¡£¡£¡£¡£¡£
ÔÙÉúÔªÐû²¼½«À©´óÓëIntellia TherapeuticsÏÖÓеÄÏàÖúЭÒé
2023-10-09
10ÔÂ9ÈÕ£¬£¬£¬£¬ÔÙÉúÔªÐû²¼£¬£¬£¬£¬½«À©´óÓëIntellia Therapeutics¹«Ë¾ÏÖÓеÄÏàÖúЭÒ飬£¬£¬£¬ÒÔ¿ª·¢Õë¶ÔÉñ¾­ºÍ¼¡Èâ¼²²¡µÄ»ùÓÚCRISPR/Cas9µÄ»ùÒò±à¼­ÁÆ·¨¡£¡£¡£¡£¡£¡£À©´óºóµÄЭÒ齫°ÑRegeneronµÄרÓеÝËÍϵͳºÍ¿¹Ìå°ÐÏòÏÙÏà¹Ø²¡¶¾£¨AAV£©ÔØÌåÓëIntelliaµÄNme2 CRISPR/Cas9»ùÒò±à¼­¼¼ÊõÁ¬ÏµÆðÀ´¡£¡£¡£¡£¡£¡£ÔÙÉúÔªÓëIntelliaºã¾Ã¶ø¸»ÓÐЧ¹ûµÄÏàÖúÕýÔÚʹÓÃм¼ÊõºÍÁ¢ÒìÐÔÀ´ÊÍ·Å»ùÒòÒ©ÎïµÄDZÁ¦£¬£¬£¬£¬´Ë´ÎÏàÖúÕýÊÇÃé×¼ÁËÉñ¾­ºÍ¼¡Èâ¼²²¡¡£¡£¡£¡£¡£¡£
³¬6ÒÚÃÀÔª£¡°¶ÂõÉúÎïBCMA/CD3Ë«¿¹»ùÓÚ×ÔÃâ³öº£
2024-09-04
9ÔÂ4ÈÕ£¬£¬£¬£¬EpimAb Biotherapeutics, Inc. £¨°¶ÂõÉúÎ¼°Vignette Bio, Inc.£¨Vignette Bio£©ÅäºÏÐû²¼£¬£¬£¬£¬Ë«·½¾Í°¶ÂõÉúÎï°ÐÏòBCMAµÄTϸ°û½ÓºÏ£¨TCE£©·Ö×ÓEMB-06£¬£¬£¬£¬¸æ¿¢ÁËÒ»ÏîÊÚȨÔÊÐíЭÒé¡£¡£¡£¡£¡£¡£Æ¾Ö¤¸ÃЭÒé»®¶¨£¬£¬£¬£¬°¶ÂõÉúÎォÊÚÓèVignetteÔÚ´óÖлªÇø£¨°üÀ¨Öйú´ó½£¬£¬£¬£¬Ïã¸Û£¬£¬£¬£¬°ÄÃźĮ́ÍåµØÇø£©ÒÔÍ⿪·¢ºÍÉÌÒµ»¯EMB-06µÄ¶À¼ÒȨÁ¦£¬£¬£¬£¬¶ø°¶ÂõÉúÎォ±£´æEMB-06ÔÚ´óÖлªÇøµÄȨÁ¦¡£¡£¡£¡£¡£¡£°¶ÂõÉúÎォÒÔÏÖ½ðºÍVignette¹ÉȨµÄÐÎʽÊÕÈ¡×ܼÆ6000ÍòÃÀÔªµÄÊ׸¶¿î¶Ô¼Û£¬£¬£¬£¬²¢½«ÓÐȨÊÕÈ¡×î¶à5.75ÒÚÃÀÔªµÄ¿ª·¢¡¢ÉÏÊС¢ºÍÉÌÒµ»¯µÄÀï³Ì±®¸¶¿î£¬£¬£¬£¬ÒÔ¼°»ùÓÚ¾»ÏúÊÛ¶îµÄÊÕÈë·Ö³É¡£¡£¡£¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿